BIIB - Biogen Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—General
Cambridge,
United States
Type: Equity
BIIB price evolution
BIIB
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1049.9 | $2287.9 | $2617.8 | $2898.2 |
| Short term investments | $3460.5 | $2143.1 | ||
| Net receivables | $2100 | $2209.7 | $2124 | $2028.2 |
| Inventory | $2527.4 | $2982.4 | $1333.5 | $1281 |
| Total current assets | $6859.3 | $8454.1 | $10431.7 | $9762.5 |
| Long term investments | $745 | $754.7 | $2312.9 | $2359 |
| Property, plant & equipment | $3729.7 | $3762.5 | $3673.7 | $3700 |
| Goodwill & intangible assets | $14582.2 | $14152.1 | $7530.1 | $7565.1 |
| Total noncurrent assets | $19985.5 | $19739.1 | $14725.1 | $14835.9 |
| Total investments | $745 | $754.7 | $5773.4 | $4502.1 |
| Total assets | $26844.8 | $28193.2 | $25156.8 | $24598.4 |
| Current liabilities | ||||
| Accounts payable | $403.3 | $440.1 | $445.4 | $491.2 |
| Deferred revenue | ||||
| Short long term debt | $150 | $500 | ||
| Total current liabilities | $3434.3 | $5022.3 | $3186.5 | $3014.9 |
| Long term debt | $7188.2 | $7215.2 | $6589 | $6609.7 |
| Total noncurrent liabilities | $8611.1 | $8691.2 | $7509.8 | $7796.5 |
| Total debt | $7338.2 | $7715.2 | $6589 | $6609.7 |
| Total liabilities | $12045.4 | $13713.5 | $10696.3 | $10811.4 |
| Shareholders' equity | ||||
| Retained earnings | $17627.6 | $17377.9 | $17446 | $16854.4 |
| Other shareholder equity | -$153.7 | -$159.3 | -$172.8 | -$172 |
| Total shareholder equity | $14799.4 | $14483.8 | $14466.9 | $13796.6 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1049.9 | $3419.3 | $2261.4 | $1331.2 |
| Short term investments | $1473.5 | $1541.1 | $1278.9 | |
| Net receivables | $2100 | $2136.4 | $1961.7 | $2327.3 |
| Inventory | $2527.4 | $1344.4 | $1351.5 | $1068.6 |
| Total current assets | $6859.3 | $9791.2 | $7856.5 | $6887.1 |
| Long term investments | $745 | $2234.9 | $2831.5 | $3671.1 |
| Property, plant & equipment | $3729.7 | $3702.5 | $3791.8 | $3844.8 |
| Goodwill & intangible assets | $14582.2 | $7599.1 | $7982.4 | $8846.4 |
| Total noncurrent assets | $19985.5 | $14762.9 | $16020.8 | $17731.8 |
| Total investments | $745 | $3708.4 | $4372.6 | $4950 |
| Total assets | $26844.8 | $24554.1 | $23877.3 | $24618.9 |
| Current liabilities | ||||
| Accounts payable | $403.3 | $491.5 | $589.2 | $454.9 |
| Deferred revenue | ||||
| Short long term debt | $150 | $999.1 | ||
| Total current liabilities | $3434.3 | $3272.8 | $4298.2 | $3742.2 |
| Long term debt | $7188.2 | $6281 | $6604.4 | $7828.2 |
| Total noncurrent liabilities | $8611.1 | $7892.9 | $8619.4 | $10190.6 |
| Total debt | $7338.2 | $6614 | $7603.5 | $7828.2 |
| Total liabilities | $12045.4 | $11156.2 | $12917.6 | $13932.8 |
| Shareholders' equity | ||||
| Retained earnings | $17627.6 | $16466.5 | $13911.7 | $13976.3 |
| Other shareholder equity | -$153.7 | -$149.2 | -$106.7 | -$299 |
| Total shareholder equity | $14799.4 | $13397.9 | $10896.2 | $10700.3 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2386.3 | $2530.3 | $2456 | $2463 |
| Cost of revenue | $618.3 | $659.6 | $592.7 | $662.8 |
| Gross Profit | $1768 | $1870.7 | $1863.3 | $1800.2 |
| Operating activities | ||||
| Research & development | $570.9 | $736.3 | $584.2 | $570.6 |
| Selling, general & administrative | $608.5 | $788.2 | $548 | $605 |
| Total operating expenses | $1476.4 | $2011.9 | $1155.2 | $1361.9 |
| Operating income | $291.6 | -$141.2 | $708.1 | $438.3 |
| Income from continuing operations | ||||
| EBIT | $292.4 | -$141 | $706.4 | $438.6 |
| Income tax expense | $42.7 | -$72.9 | $114.8 | $50.7 |
| Interest expense | ||||
| Net income | ||||
| Net income | $249.7 | -$68.1 | $591.6 | $387.9 |
| Income (for common shares) | $249.7 | -$68.1 | $591.6 | $387.9 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9835.6 | $10173.4 | $10981.7 | $13444.6 |
| Cost of revenue | $2533.4 | $2278.3 | $2109.7 | $1805.2 |
| Gross Profit | $7302.2 | $7895.1 | $8872 | $11639.4 |
| Operating activities | ||||
| Research & development | $2462 | $2231.1 | $2501.2 | $3990.9 |
| Selling, general & administrative | $2549.7 | $2403.6 | $2674.3 | $2504.5 |
| Total operating expenses | $6005.4 | $4303.3 | $6031.3 | $7089.3 |
| Operating income | $1296.8 | $3591.8 | $2840.7 | $4550.1 |
| Income from continuing operations | ||||
| EBIT | $1296.4 | $3679.7 | $1608.6 | $4992.9 |
| Income tax expense | $135.3 | $632.8 | $52.5 | $992.3 |
| Interest expense | ||||
| Net income | ||||
| Net income | $1161.1 | $3046.9 | $1556.1 | $4000.6 |
| Income (for common shares) | $1161.1 | $3046.9 | $1556.1 | $4000.6 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $249.7 | -$68.1 | $591.6 | $387.9 |
| Operating activities | ||||
| Depreciation | $140.1 | $125 | $117.4 | $112.3 |
| Business acquisitions & disposals | -$590.5 | -$6335.6 | $788.1 | |
| Stock-based compensation | $54.9 | $62.2 | $71.5 | $75.6 |
| Total cash flows from operations | $12.5 | $592.4 | $487 | $455.3 |
| Investing activities | ||||
| Capital expenditures | -$65.2 | -$87.6 | -$87 | -$71.6 |
| Investments | $13.4 | $4681.2 | -$1454.2 | -$880.7 |
| Total cash flows from investing | -$652.3 | -$1742.2 | -$753.5 | -$953 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$650 | $837.3 | ||
| Total cash flows from financing | -$646.1 | $848.6 | -$9.8 | -$43.4 |
| Effect of exchange rate | $47.9 | -$28.7 | -$4.1 | $20 |
| Change in cash and equivalents | -$1285.9 | -$301.2 | -$276.3 | -$541.1 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $1161.1 | $3046.9 | $1556.1 | $4000.6 |
| Operating activities | ||||
| Depreciation | $494.8 | $638 | $1117 | $666.9 |
| Business acquisitions & disposals | -$6138 | $990.3 | $28.1 | -$1006.5 |
| Stock-based compensation | $264.2 | $254.1 | $238.6 | $198.3 |
| Total cash flows from operations | $1547.2 | $1384.3 | $3639.9 | $4229.8 |
| Investing activities | ||||
| Capital expenditures | -$311.4 | $339.4 | -$276.9 | -$476.8 |
| Investments | $2359.7 | $222.5 | -$309.8 | $976.6 |
| Total cash flows from investing | -$4101 | $1576.6 | -$563.7 | -$608.6 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$750 | -$1800 | -$6679.1 | |
| Net borrowings | $187.3 | -$1002.2 | -$170 | $1467.4 |
| Total cash flows from financing | $149.3 | -$1747.3 | -$2086.2 | -$5272.7 |
| Effect of exchange rate | $35.1 | -$55.7 | -$59.8 | $69 |
| Change in cash and equivalents | -$2404.5 | $1213.6 | $990 | -$1651.5 |
News
|
Biogen’s stock climbs as first-quarter profit tops estimates, Alzheimer’s drug uptake improves
Market Watch
24 Apr 2024
|
|
Should You Be Confident in Biogen (BIIB)?
Insider Monkey via Yahoo Finance
23 Apr 2024
|
|
Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
Zacks via Yahoo Finance
17 Apr 2024
|
|
Medicare spending on Biogen’s Alzheimer's drug to hit $3.5B
Seeking Alpha
16 Apr 2024
|
|
US biopharma first quarter earnings seen stable amid low expectations
Proactive Investors
12 Apr 2024
|
|
GLP-1s benefit Parkinson’s: Barclays sees biopharma impact
Seeking Alpha
12 Apr 2024
|
|
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
Zacks via Yahoo Finance
11 Apr 2024
|
|
12 Best Depressed Stocks To Buy in 2024
Insider Monkey via Yahoo Finance
10 Apr 2024
|
|
Thermo Fisher CEO's compensation dropped by 33% last year - Boston Business Journal
The Business Journals
9 Apr 2024
|
|
Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst
Seeking Alpha
7 Apr 2024
|
Fundamentals
| Market cap | $29.27B |
|---|---|
| Enterprise value | $35.56B |
| Shares outstanding | 144.90M |
| Revenue | $9.84B |
|---|---|
| EBITDA | $1.79B |
| EBIT | $1.30B |
| Net Income | $1.16B |
| Revenue Q/Q | -6.20% |
| Revenue Y/Y | -3.32% |
| P/E ratio | 25.21 |
|---|---|
| EV/Sales | 3.62 |
| EV/EBITDA | 19.85 |
| EV/EBIT | 27.43 |
| P/S ratio | 2.98 |
| P/B ratio | 1.96 |
| Book/Share | 103.20 |
| Cash/Share | 7.25 |
| EPS | $8.01 |
|---|---|
| ROA | 4.43% |
| ROE | 8.07% |
| Debt/Equity | 0.81 |
|---|---|
| Net debt/EBITDA | 6.14 |
| Current ratio | 2.00 |
| Quick ratio | 1.26 |